Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

The Lancet. Diabetes & Endocrinology
Bernhard LudvikZvonko Milicevic

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce bodyweight in patients with type 2 diabetes through different mechanisms. We assessed the safety and efficacy of the addition of the once-weekly GLP-1 receptor agonist dulaglutide to the ongoing treatment regimen in patients whose diabetes is inadequately controlled with SGLT2 inhibitors, with or without metformin. AWARD-10 was a phase 3b, double-blind, parallel-arm, placebo-controlled, 24-week study done at 40 clinical sites in Austria, Czech Republic, Germany, Hungary, Israel, Mexico, Spain, and the USA. Eligible adult patients (≥18 years) with inadequately controlled type 2 diabetes (HbA1c concentration ≥7·0% [53 mmol/mol] and ≤9·5% [80 mmol/mol]), a BMI of 45 kg/m2 or less, and taking stable doses (>3 months) of an SGLT2 inhibitor (with or without metformin) were randomly assigned (1:1:1) via an interactive web-response system to subcutaneous injections of either dulaglutide 1·5 mg, dulaglutide 0·75 mg, or placebo once per week for 24 weeks. Patients and investigators were masked to dulaglutide and placebo assignment, and those assessing outcomes were masked to study drug assignment. ...Continue Reading

Citations

Apr 7, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Edison Goncalves, David S H Bell
Mar 25, 2018·Journal of Diabetes·Ann M CarracherKelly L Close
May 24, 2018·Expert Opinion on Pharmacotherapy·Kashif M Munir, Stephen N Davis
Jun 16, 2018·Endocrine Reviews·Megan E CapozziJonathan E Campbell
Dec 7, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Irene RomeraJesús Reviriego
Feb 7, 2019·Expert Review of Endocrinology & Metabolism·Juan Pablo Frias
Apr 12, 2019·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Emily BrownDaniel J Cuthbertson
Oct 11, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Solomon NuhohoAbby Paine
Oct 13, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Hiren PatelManige Konig
Oct 28, 2019·Diabetes, Obesity & Metabolism·Louis S MatzaLuis-Emilio García-Pérez
Feb 29, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Richard A ChudleighStephen C Bain
Mar 15, 2020·International Journal of Molecular Sciences·Yoshio SumidaJapan Study Group Of Nafld Jsg-Nafld
Apr 18, 2020·The Journal of Clinical Endocrinology and Metabolism·Mario Luca MorieriGian Paolo Fadini
Jul 12, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Gary DeedAndrew Sindone
Jul 31, 2020·JCI Insight·Francis S WillardKyle W Sloop
Sep 10, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Xuejun Victor PengLawrence Blonde
Sep 15, 2020·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Vikas S SridharDavid Z Cherney
May 11, 2020·Current Obesity Reports·Dimitrios TsilingirisAlexander Kokkinos
Sep 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Dhiren Patel
Sep 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Jennifer Trujillo
Feb 1, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Brendon L NeuenVlado Perkovic
Nov 18, 2018·Nature Reviews. Endocrinology·Christoffer ClemmensenSusanna M Hofmann
Dec 24, 2018·Expert Opinion on Pharmacotherapy·Javier Gargallo-VaamondeJavier Salvador
Mar 2, 2019·Cardiovascular Diabetology·Chiara Maria Assunta CefaloAndrea Giaccari
Jun 4, 2020·Diabetology & Metabolic Syndrome·Marcello Casaccia BertoluciCristiane Bauermann Leitão
Sep 29, 2020·Circulation·Janani RangaswamiUNKNOWN American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vasc
Mar 1, 2019·Endocrinology, Diabetes & Metabolism·Santiago ToféVicente Pereg
Feb 1, 2019·Drugs·Maria J Pereira, Jan W Eriksson
Jun 20, 2019·Journal of Clinical Medicine·Clara García-CarroMaría José Soler
Jul 27, 2020·Endocrinology, Diabetes & Metabolism·Vasiliki Mittag-RoussouCaroline S Stokes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

© 2022 Meta ULC. All rights reserved